title: Statistical identification of predictors for paclitaxel-induced peripheral neuropathy in patients with breast or gynaecological cancer.
abstract: OBJECTIVE
  The aim of this study was to identify predictors for paclitaxel-induced peripheral neuropathy (PIPN).
  
  
  METHODS
  We conducted a retrospective analysis of 227 patients who had been treated with paclitaxel at a single institution between January 2008 and July 2011. At the time of chemotherapy completion, the severity of PIPN was graded on a scale of 0-5, in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0. Multivariate-ordered logistic regression analysis was employed to examine the relationship between various predictive factors and the occurrence of PIPN.
  
  
  RESULTS
  Diabetes mellitus [odds ratio (OR)=0.070], age (OR=1.991), co-administration of neurotropin (OR=3.654), co-administration of opioids (OR=0.312), co-administration of vitamin B12 (OR=2.554), co-administration of antidepressant (OR=4.754) and co-administration of gabapentinoids (OR=14.620), were significantly associated with reduction of or less serious PIPN.
  
  
  CONCLUSIONS
  Our study indicates that PIPN may be alleviated by co-administration of opioids.
authors.affiliation: Department of Hospital Pharmacy, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan. ykokanba@koto.kpu-m.ac.jp
authors.forename: Yuko
authors.initials: Y
authors.lastname: Kanbayashi
authors.forename: Toyoshi
authors.initials: T
authors.lastname: Hosokawa
authors.forename: Jo
authors.initials: J
authors.lastname: Kitawaki
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Taguchi
mesh_terms: D000368:Aged; D000701:Analgesics, Opioid / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D017239:Paclitaxel / Q000009:adverse effects*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000188:drug therapy; D000069583:Pregabalin; D012189:Retrospective Studies; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000701:Analgesics, Opioid; D000972:Antineoplastic Agents, Phytogenic; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid; D017239:Paclitaxel